BioTTT001
AXP000046.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, triple-deleted: E1ACR2, E1B19K, E3gp19K)
- Originator
- Capital Medical University
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology
Names
| Name | Type | Source |
|---|---|---|
| BioTTT001 | preferred name, code | curator, ncit |
| Ad-TD-nsIL12 | code | ctgov |
| Ad5-TD-nsIL-12 | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (Ad-TD)
- Replication
- conditionally replicating
- Modifications
- triple deletion: E1A CR2, E1B-19K and E3gp19K
- Transgenes
- IL12A, IL12B (non-secreting)
- Route
- intratumoral, intraperitoneal, intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C205444
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07472790 | A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma | Not yet recruiting | Phase 1 | 2026-07-31 | 2028-04-30 | 15 | High-grade Glioma |
| NCT06283134 | A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | Not yet recruiting | Phase 1 | 2026-03 | 2027-12-01 | 60 | Colorectal Cancer Metastatic |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | Recruiting | Phase 1/2 | 2025-06-25 | 2027-12-30 | 42 | Meningeal Metastasis |
| NCT07150767 | A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer | Withdrawn | Phase 1 | 2025-03-26 | 2027-03-26 | 0 | Locally Advanced Breast Cancer (LABC) |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | Enrolling by invitation | Phase 1/2 | 2025-02-12 | 2028-08-30 | 40 | Glioma |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | Enrolling by invitation | Phase 1/2 | 2024-11-26 | 2027-07-31 | 30 | Recurrent High-grade Glioma |
| NCT06215846 | A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors | Enrolling by invitation | Phase 1 | 2024-05-07 | 2026-05-30 | 12 | Solid Tumor |
| NCT06283121 | A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer | Not yet recruiting | Phase 2 | 2024-04-02 | 2027-11-30 | 30 | Gastric Cancer, Metastatic |
| NCT05717712 | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | Recruiting | Phase 1 | 2023-01-04 | 2025-01-04 | 18 | Adverse Drug Event; Diffuse Intrinsic Pontine Glioma; Oncolytic Virus |
| NCT05717699 | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | Recruiting | Phase 1 | 2023-01-04 | 2025-01-04 | 18 | Adverse Drug Event; Diffuse Intrinsic Pontine Glioma; Oncolytic Virus |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40721414 | The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials. | Nature communications | 2025 | name in title: Ad-TD-nsIL12 |
| PMID 39114662 | Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review. | Frontiers in immunology | 2024 | name in title: Ad-TD-nsIL12 |
| PMID 39516192 | Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial. | Nature communications | 2024 | name in title: Ad-TD-nsIL12 |
| PMID 33182528 | A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma. | Cells | 2020 | cited by trial NCT05717712 |
| PMID 29123084 | Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. | Nature communications | 2017 | cited by trial NCT05717712 |
| PMID 19223865 | Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | cited by trial NCT05717712 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: Ad-TD-nsIL12 |
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: Ad-TD-nsIL12 |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: Ad-TD-nsIL12 |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: Ad-TD-nsIL12 |
Notes
Also written Ad-TD-nsIL12 / Ad5-TD-nsIL-12. The academic trials run by Capital Medical University (NCT05717712, NCT05717699) and the company trials of BioTTT001 appear to be the same construct; merged here on the strength of the NCIt synonym Ad5-TD-nsIL-12. Worth a curator check.
How to cite
BioTTT001 (AXP000046.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000046.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.